ACCOUNT

SECTIONS

HOME
- Homepage
- This Just In
- Chats
- Weather
- Traffic
- Event Guide
- PG Store
- PGe
- Video
- Photos
- The Digs
- RSS Feeds
NEWS
- News Home
- COVID-19
- World
- Nation
- State
- Obituaries
- News Obituaries
- Politics
- Education
- Portfolio
- Science
- Health & Wellness
- Environment
- Aging Edge
- Transportation
- Faith & Religion
- Crimes & Courts
- Social Services
LOCAL
- Local Home
- Region
- City
- North
- East
- West
- South
- Washington
- Westmoreland
- The Neighborhood
- Obituaries
- Classifieds
- Legal Notices
- Real Estate
SPORTS
- Sports Home
- Steelers
- Penguins
- Pirates
- Sports Columns
- Gene Collier
- Ron Cook
- Joe Starkey
- Paul Zeise
- High School Sports
- College Sports
- Pitt
- Penn State
- WVU
- NCAA
- NFL
- MLB
- NBA
- NHL
- North Shore Drive Podcast
OPINION
A&E
- A&E Home
- Celebrities
- Movies
- TV & Radio
- Music
- Concert Listings
- Theatre & Dance
- Art & Architecture
- Books
- Events
LIFE
- Life Home
- Food
- Buying Here
- Homes & Gardens
- Style & Fashion
- Travel
- Restaurants
- Seen
- goodness
- Random Acts of Kindness
- Pets
- Beer Me
- Outdoors
- Holidays
BUSINESS

OTHER

CLASSIFIEDS

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Ocular Therapeutix, Inc. - Common Stock (NQ:OCUL)

8.585 -0.005 (-0.06%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	823
Open	8.585
Bid (Size)	8.570 (200)
Ask (Size)	8.870 (100)
Prev. Close	8.590
Today's Range	8.585 - 8.585
52wk Range	6.230 - 16.44
Shares Outstanding	157,749,490
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Ocular Therapeutix Eyes Q4 AXPAXLI NDA After FDA Alignment ↗

July 22, 2026

Ocular Therapeutix (NASDAQ:OCUL) said it remains on track to submit a New Drug Application for AXPAXLI in wet age-related macular degeneration in the fourth quarter, after what Executive Chairman,...

Via MarketBeat

3 Cash-Burning Stocks with Open Questions

July 21, 2026

While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sh...

Via StockStory

Performance

YTD	-27.4%	-27.4%
1 Month	-13.9%	-13.9%
3 Month	-11.1%	-11.1%
6 Month	-24.8%	-24.8%
1 Year	-25.7%	-25.7%

More News

3 Small-Cap Stocks with Open Questions

July 08, 2026

Via StockStory

Ocular Therapeutix (OCUL): Buy, Sell, or Hold Post Q1 Earnings?

June 24, 2026

Via StockStory

Ocular Therapeutix Inc (NASDAQ:OCUL) Misses on Revenue and EPS in Q1 2026, Stock Dips ↗

May 05, 2026

Via Chartmill

Stocks making big moves yesterday: Nubank, Ocular Therapeutix, Mondelez, ResMed, and Sonos

June 18, 2026

Via StockStory

Why Ocular Therapeutix (OCUL) Stock Is Up Today

June 17, 2026

Via StockStory

Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026? ↗

June 15, 2026

Via The Motley Fool

3 of Wall Street’s Favorite Stocks That Concern Us

June 10, 2026

Via StockStory

1 Russell 2000 Stock to Research Further and 2 Facing Headwinds

May 28, 2026

Via StockStory

Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1 ↗

May 26, 2026

Via The Motley Fool

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors ↗

May 19, 2026

Via The Motley Fool

Why Ocular Therapeutix (OCUL) Stock Is Nosediving

May 05, 2026

Via StockStory

Ocular Therapeutix (NASDAQ:OCUL) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings

May 05, 2026

Via StockStory

Ocular Therapeutix (OCUL) To Report Earnings Tomorrow: Here Is What To Expect

May 03, 2026

Via StockStory

1 Healthcare Stock with Exciting Potential and 2 Facing Headwinds

April 02, 2026

Via StockStory

Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗

March 18, 2026

Via The Motley Fool

What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗

March 18, 2026

Via The Motley Fool

1 Cash-Heavy Stock to Research Further and 2 We Brush Off

March 18, 2026

Via StockStory

3 Reasons to Avoid OCUL and 1 Stock to Buy Instead

March 17, 2026

Via StockStory

3 Stocks Under $10 We Think Twice About

March 16, 2026

Via StockStory

Pharmaceuticals Stocks Q4 Highlights: Ocular Therapeutix (NASDAQ:OCUL)

March 11, 2026

Via StockStory

3 Small-Cap Stocks We’re Skeptical Of

March 05, 2026

Via StockStory

3 of Wall Street’s Favorite Stocks We’re Skeptical Of

March 04, 2026

Via StockStory

Ocular Therapeutix (OCUL) Stock Trades Down, Here Is Why

February 27, 2026

Via StockStory

Frequently Asked Questions

Is Ocular Therapeutix, Inc. - Common Stock publicly traded?

Yes, Ocular Therapeutix, Inc. - Common Stock is publicly traded.

What exchange does Ocular Therapeutix, Inc. - Common Stock trade on?

Ocular Therapeutix, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Ocular Therapeutix, Inc. - Common Stock?

The ticker symbol for Ocular Therapeutix, Inc. - Common Stock is OCUL on the Nasdaq Stock Market

What is the current price of Ocular Therapeutix, Inc. - Common Stock?

The current price of Ocular Therapeutix, Inc. - Common Stock is 8.585

When was Ocular Therapeutix, Inc. - Common Stock last traded?

The last trade of Ocular Therapeutix, Inc. - Common Stock was at 07/22/26 04:00 PM ET

What is the market capitalization of Ocular Therapeutix, Inc. - Common Stock?

The market capitalization of Ocular Therapeutix, Inc. - Common Stock is 1.35B

How many shares of Ocular Therapeutix, Inc. - Common Stock are outstanding?

Ocular Therapeutix, Inc. - Common Stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.